[THE INVESTOR] Boryung Pharmaceutical on June 20 clinched a deal with Sandoz, the generic division of Swiss drug maker Novartis, to export its anti-hypertension drug Cilnidipine to Southeast Asian countries.

Under the contract, Boryung will provide US$ 73 million worth of drugs through Sandoz to six countries, including Thailand, Philippines, Malaysia, Singapore, Taiwan and Hong Kong over the 10 year period.

“Based on the experience from Knarb’s marketing abroad, we will increase our brand’s value in the anti-hypertension market in Southeast Asian countries,” Choi Tae-hong, CEO of Boryung said.

By Ahn Sung-mi (sahn@heraldcorp.com)